1. Protein Tyrosine Kinase/RTK
    Cell Cycle/DNA Damage
  2. c-Kit
    PDGFR
    RAD51
    FLT3
    c-Met/HGFR
    RET
  3. Amuvatinib hydrochloride

Amuvatinib hydrochloride (Synonyms: MP470 hydrochloride; HPK 56 hydrochloride)

目录号: HY-10206A
产品使用指南

Amuvatinib hydrochloride (MP470 hydrochloride) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-KitPDGFRαFlt3c-Metc-Ret 具有有效活性。Amuvatinib hydrochloride (MP470 hydrochloride) 还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复。具有抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Amuvatinib hydrochloride Chemical Structure

Amuvatinib hydrochloride Chemical Structure

CAS No. : 1055986-67-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Amuvatinib hydrochloride 的其他形式现货产品:

Customer Review

Other Forms of Amuvatinib hydrochloride:

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

查看 PDGFR 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair[1][2][3]. Antineoplastic activity[4].

IC50 & Target[1]

PDGFRαV561D

40 nM (IC50)

PDGFRαD842V

81 nM (IC50)

c-KitD816H

10 nM (IC50)

c-KitV560G

34 nM (IC50)

c-KitV654A

127 nM (IC50)

c-KitD816V

950 nM (IC50)

体外研究
(In Vitro)

Amuvatinib (MP470) inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D) with IC50s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively[4].
Amuvatinib (MP470), a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines. Amuvatinib (0.1-10 μM, 4 days incubation) is effective on LNCaP and PC-3 cells with IC50s of ~4 μM and 8 μM, respectively. When Erlotinib (10 μM) is combined with varying doses of Amuvatinib, the IC50 of Amuvatinib decreases to 2 μM on LNCaP cells[5].
Akt activity (as measured by phosphorylation on Ser473) is significantly reduced by 10 μM Amuvatinib (treated for 30 hours) alone but is not reduced by Erlotinib or Imatinib Mesylate (IM). Moreover, Amuvatinib plus Erlotinib completely abolished Akt phosphorylation in LNCaP cells with an unchanged total protein level of Akt[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: Prostate cancer cell lines (LNCaP, PC-3 and DU-145)
Concentration: 0.1-10 μM
Incubation Time: 4 days
Result: The IC50 for LNCaP and PC-3 was ~4 μM and 8 μM, respectively. Had only a modest effect on the viability of DU-145 cells.

Western Blot Analysis[2]

Cell Line: LNCaP cells
Concentration: 2,5,10 μM
Incubation Time: 30 hours
Result: Akt activity (as measured by phosphorylation on Ser473) was significantly reduced at 10 μM.
体内研究
(In Vivo)

Four LNCaP xenograft arms each with 12 mice are dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or Amuvatinib (MP470) 50 mg/kg or Erlotinib 80 mg/kg plus Amuvatinib 50 mg/kg daily for 2 weeks and then observed for a further 11 days. Individual therapy with Amuvatinib or Erlotinib shows modest tumor growth inhibition (TGI), while Amuvatinib plus Erlotinib has a marked effect on TGI (45-65%). However, due to the high doses of Amuvatinib used, only five or one mouse remained alive in the combination arm at the end of treatment or at the end of the study, respectively. Therefore the Amuvatinib dose is reduced to 10 mg/kg or 20 mg/kg for the combination treatment. TGI in the group receiving 10 mg/kg Amuvatinib+80 mg/kg Erlotinib is not significantly different from the control group. However, mice receiving 20 mg/kg Amuvatinib+80 mg/kg Erlotinib have a significant TGI compared to the control group (p=0.01)[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Forty eight 6-7 week-old SCID male mice with LNCaP xenograft model[2]
Dosage: 10 mg/kg and 20 mg/kg, 50 mg/kg
Administration: Administered i.p. daily from days 1 to 24
Result: Individual therapy showed modest tumor growth inhibition (TGI), while combination had a marked effect on TGI (45-65%).
Clinical Trial
Formula

C23H21N5O3S.xHCl

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Amuvatinib hydrochloride
目录号:
HY-10206A
需求量: